Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retigabine: in partial seizures.

Greg L Plosker1, Lesley J Scott

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|June 28, 2006
PubMed
Summary

Retigabine, an anticonvulsant, effectively reduces partial seizure frequency by opening potassium channels. Higher doses showed greater efficacy, though central nervous system side effects were common.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Retigabine exhibits anticonvulsant properties.
  • Its primary mechanism involves opening neuronal voltage-gated potassium channels, specifically KCNQ2/3 and KCNQ3/5 channels.
  • At higher concentrations, it potentiates GABA-evoked currents in cortical neurons.

Purpose of the Study:

  • To evaluate the efficacy and safety of retigabine as adjunctive therapy for partial seizures.

Main Methods:

  • A large, 16-week randomized phase II trial.
  • Patients received retigabine 600-1200 mg/day or placebo as adjunctive therapy.
  • Seizure frequency and responder rates were primary endpoints.

Main Results:

  • Retigabine demonstrated a significant, dose-dependent reduction in monthly seizure frequency compared to placebo.
  • Median seizure frequency decreased by up to 35% with retigabine versus 13% with placebo.
  • Higher doses (900-1200 mg/day) showed significantly higher responder rates (> or = 50% reduction).

Conclusions:

  • Retigabine is an effective adjunctive treatment for partial seizures.
  • Dose-dependent efficacy was observed, with higher doses providing greater seizure reduction.
  • Common adverse events were CNS-related, including somnolence, dizziness, confusion, and speech disorder.

Related Experiment Videos